Loading...
XMAD
FAE
Market cap1.65bUSD
Jun 18, Last price  
4.53EUR
1D
-1.95%
1Q
2.49%
Jan 2017
34.82%
Name

Faes Farma SA

Chart & Performance

D1W1MN
XMAD:FAE chart
P/E
12.66
P/S
2.86
EPS
0.36
Div Yield, %
3.87%
Shrs. gr., 5y
2.51%
Rev. gr., 5y
6.67%
Revenues
494m
+9.42%
166,449,000185,187,000185,940,000194,180,000131,406,000202,507,000190,224,000176,109,000180,394,000191,742,000204,724,000228,635,000274,576,000324,312,000357,398,000380,240,000398,557,000438,754,000451,168,000493,647,000
Net income
111m
+21.17%
23,273,00022,772,00022,149,00019,615,00018,161,00020,002,00014,181,00019,518,00022,605,00025,334,00030,361,00036,591,00042,221,00051,592,00063,962,00072,549,00082,390,00089,496,00091,902,000111,360,000
CFO
115m
+14.36%
19,930,00013,044,00034,308,00016,946,00015,238,00019,975,00023,872,00031,647,00032,259,00040,912,00049,625,00041,727,00059,336,00067,585,00078,489,00079,645,000106,788,000100,969,000115,468,000
Dividend
Jan 08, 20260.03321 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
IPO date
Mar 25, 1994
Employees
1,764
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT